FDA Proposed Master Protocol For Zykadia Trial; Novartis Had Other Plans
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA floated the idea of using a master protocol to provide the required confirmation of clinical benefit for ceritinib’s accelerated approval, but Novartis chose to rely on two traditional Phase III trials, either of which could meet the regulatory standard.